ΒΆ gut dysbiosis
ΒΆ Definition
Gut dysbiosis is a pathological disruption of the gut microbiome characterized by reduced microbial diversity (typically <50 operational taxonomic units in Western populations versus >150 in traditional populations), depletion of keystone commensalsβespecially Faecalibacterium prausnitzii, Bifidobacterium, and Akkermansia-muciniphilaβand overgrowth of pathobionts including Proteobacteria (Enterobacteriaceae, Escherichia), Clostridium difficile, and pro-inflammatory Bacteroidetes species. This imbalance disrupts metabolic outputs (SCFA production drops 40-70%), compromises gut barrier integrity (increasing intestinal permeability 2-5 fold), and triggers chronic low-grade inflammation via LPS translocation and impaired immune tolerance.
ΒΆ Picture It
Imagine a thriving rainforest suddenly degraded into a sparse scrubland dominated by weeds. The rainforest (healthy microbiome) has thousands of speciesβtrees producing oxygen (Butyrate-producing bacteria), nitrogen-fixing plants (immune-regulating commensals), and species that maintain soil structure (gut barrier integrity). A wildfire (antibiotics) or drought (low-fiber Western diet) kills the diverse canopy, leaving bare ground. Opportunistic weeds (LPS-producing Proteobacteria, pathobionts) colonize rapidlyβthey grow fast but produce toxins instead of nutrients. Without trees, the topsoil erodes (barrier breakdown). Without nitrogen-fixers, crops fail (metabolic dysfunction). Without biodiversity, local weather becomes erratic (immune dysregulation). The scrubland can't self-restore; it needs deliberate replanting (fiber, prebiotics) and fire prevention (antibiotics stewardship) to return to rainforest. Even introducing new trees (probiotics) won't help if the soil (dietary substrate) remains depleted.
ΒΆ Mechanism
Dysbiosis arises through multiple converging pathways:
Antibiotic-Induced Dysbiosis:
antibiotics β non-selective bacterial killing β 25-50% diversity reduction β depletion of obligate anaerobes (Faecalibacterium, Bifidobacterium, Akkermansia) β bloom of antibiotic-resistant facultative anaerobes (Enterobacteriaceae) β reduced SCFA production (especially Butyrate drops from 15-20 mM to 5-10 mM in colonic lumen) β impaired colonocyte energy metabolism β gut barrier dysfunction β recovery requires 6-12+ months
Diet-Induced Dysbiosis:
Low fiber (<15g/day) + high fat/sugar Western diet β reduced fermentable substrate β starvation of SCFA-producers β bloom of bile acid-tolerant Bacteroidetes and Proteobacteria β LPS production increases 2-3 fold β reduced mucin production β thinning of mucus layer (from 700-800 ΞΌm to <200 ΞΌm) β bacteria-epithelium contact β TLR4 activation β NF-kB β IL-6, TNF-Ξ± β chronic inflammation
Stress-Induced Dysbiosis:
chronic stress β Cortisol elevation β sympathetic dominance β reduced splanchnic blood flow β ischemic gut mucosa β Noradrenaline secretion into gut lumen β pathobiont growth stimulation (via bacterial adrenergic receptors) β virulence factor upregulation β invasion of gut barrier β stress-induced intestinal permeability
Dysbiosis Cascade:
Loss of keystone species β reduced Butyrate (primary fuel for colonocytes) β colonocyte energy deficit β tight junctions disassembly (occludin, ZO-1 downregulation) β paracellular permeability β LPS translocation β systemic Endotoxaemia (plasma LPS >50 pg/mL) β hepatic TLR4 activation β acute phase response β C-reactive protein elevation β peripheral tissue inflammation
Metabolic Consequences:
Dysbiosis β reduced SCFA production (acetate, propionate, Butyrate) β impaired GPR41, GPR43, GPR109A signaling β reduced GLP-1 secretion from enteroendocrine L-cells β impaired glucose homeostasis β Insulin resistance β reduced PGC-1alpha β mitochondrial dysfunction
Immune Dysregulation:
Healthy microbiome β Butyrate + polysaccharide A β Treg expansion (via TGF-beta + retinoic acid from RALDH2-expressing dendritic cells) β IL-10 production β immune tolerance. Dysbiosis β loss of Treg induction β Th1/Th17 skewing β IL-17, IFN-Ξ³ β barrier inflammation β autoimmune disease susceptibility
Secondary Metabolite Disruption:
Dysbiosis β impaired bile acid deconjugation β reduced secondary bile acids (deoxycholic acid, lithocholic acid) β impaired TGR5, FXR signaling β metabolic dysfunction. Dysbiosis β impaired Tryptophan metabolism β reduced indole derivatives β reduced Aryl hydrocarbon receptor activation β loss of IL-22 production from innate lymphoid cells β impaired antimicrobial peptide production
ΒΆ Clinical Significance
Gut dysbiosis is a central pathogenic mechanism across the chronic low-grade inflammation spectrum, directly relevant to cPNI practice in:
Metabolic Disorders:
Dysbiosis drives obesity (via reduced SCFA production β impaired satiety signaling), Type 2 Diabetes (via Endotoxaemia β hepatic Insulin resistance), and NAFLD (via choline metabolism dysregulation by dysbiotic bacteria producing trimethylamine β hepatic TMAO β lipid accumulation). Fecal Butyrate <5 mM predicts metabolic syndrome with 78% sensitivity.
Autoimmune Conditions:
Dysbiosis is implicated in rheumatoid arthritis (Prevotella copri overgrowth triggers anti-citrullinated protein antibodies via Molecular Mimicry), inflammatory bowel disease (Faecalibacterium depletion correlates with disease severity in Crohn's disease and Ulcerative Colitis), Type 1 Diabetes (dysbiosis precedes autoantibody development by 6-18 months), and Multiple Sclerosis (reduced SCFA-producers correlate with reduced Treg function and increased relapse rate).
Neuropsychiatric Disorders:
Via gut-brain axis, dysbiosis contributes to Depression (reduced Tryptophan metabolism β decreased serotonin precursors; increased kynurenine pathway β Quinolinic acid β NMDA receptor excitotoxicity), Anxiety (via vagus nerve inflammatory signaling), and cognitive decline (via systemic IL-6 β hippocampal neuroinflammation β impaired neurogenesis).
Evolutionary Mismatch Context:
Dysbiosis represents catastrophic loss of co-evolved symbiotic partners. Hunter-gatherer microbiome diversity (150-200 species) reflects 2.5 million years of coevolution; Western dysbiosis (40-60 species) reflects 3-4 generations of antibiotics, processed food, and hygienic excess. The selfish immune system interprets dysbiosis as pathogen invasion, activating chronic inflammation as a "better safe than sorry" defense, even though no true pathogen is present.
Assessment:
- Comprehensive stool analysis: Shannon diversity index
.5 indicates dysbiosis; Faecalibacterium <5% of total bacteria is red flag - Calprotectin >50 ΞΌg/g indicates intestinal inflammation secondary to dysbiosis
- Plasma LPS >50 pg/mL or LPS-binding protein >10 ΞΌg/mL confirms Endotoxaemia
- Plasma Butyrate <2 ΞΌM (normally 5-10 ΞΌM) indicates colonic SCFA depletion
- Urinary indole/skatole metabolites assess Tryptophan metabolism capacity
Intervention Priorities:
- Remove triggers: Minimize antibiotics, NSAIDs, proton pump inhibitors; address chronic stress via HRV training, sleep optimization
- Restore substrate: Increase dietary fiber to 40-50g/day; focus on diverse fermentable fibers (resistant starch, inulin, beta-glucans)
- Reinoculate selectively: probiotics (Lactobacillus plantarum, Bifidobacterium longum, Saccharomyces boulardii) provide temporary relief but require continuous dietary support; fecal microbiota transplantation for severe dysbiosis (C. difficile, refractory Ulcerative Colitis)
- Support barrier: L-Glutamine 5g 3x/day, Zinc 30mg/day, Vitamin D sufficiency (>75 nmol/L), Omega-3 >2g EPA/DHA daily
- Resolve inflammation: Specialized pro-resolving mediators (SPMs), Curcumin, Omega-3 fatty acids
ΒΆ Key Facts
- Western populations show 30-40% lower microbial diversity than traditional populations; urbanization correlates with diversity loss (Shannon index 4.5 β 2.8 over 2 generations)
- Single antibiotic course reduces diversity by 25-50%; broad-spectrum antibiotics (fluoroquinolones, cephalosporins) cause 6-12 month recovery; some species never return
- Dysbiosis reduces fecal Butyrate from 15-20 mM to 5-10 mM (40-70% reduction), directly impairing colonocyte ATP production and tight junctions maintenance
- Faecalibacterium prausnitzii abundance <5% of total microbiome predicts inflammatory bowel disease, Type 2 Diabetes, and depression with 70-85% specificity
- High-fat Western diet (>40% calories from fat) induces dysbiosis within 24 hours, promoting bile acid-tolerant Bacteroides and LPS-producing Enterobacteriaceae
- Dysbiosis increases intestinal permeability 2-5 fold (measured by lactulose/mannitol ratio >0.03 or zonulin >40 ng/mL), allowing bacterial translocation to mesenteric lymph nodes
- Reduced microbial diversity correlates with elevated C-reactive protein (CRP >3 mg/L in 68% of dysbiotic individuals vs 22% in healthy controls)
- probiotics provide temporary colonization (2-4 weeks) but rarely permanently alter dysbiotic microbiome without sustained dietary fiber increase to >40g/day
- chronic stress reduces Lactobacillus and Bifidobacterium by 30-60% within 2 weeks via Noradrenaline-mediated pathobiont growth stimulation
- Dysbiosis-driven Endotoxaemia (plasma LPS >50 pg/mL) increases cardiovascular disease risk 2.3-fold independent of traditional risk factors
ΒΆ Connections
- gut microbiome β dysbiosis represents the pathological state of microbiome composition, function, and metabolic output; healthy microbiome maintains >100 species diversity with dominance of SCFA-producers
- Faecalibacterium prausnitzii β keystone species accounting for 5-15% of healthy microbiome; primary Butyrate producer; depletion is hallmark biomarker of dysbiosis across metabolic and autoimmune diseases
- Butyrate β production drops 40-70% in dysbiosis, eliminating primary energy source for colonocytes and key histone deacetylase inhibitor that maintains Treg function and barrier integrity
- gut barrier β dysbiosis compromises barrier via reduced Butyrate β colonocyte energy failure, increased bacterial proteases, and mucus layer thinning from Akkermansia depletion
- intestinal permeability β dysbiosis is the primary driver, increasing paracellular permeability 2-5 fold through tight junctions disassembly and transcellular permeability through M-cell activation
- LPS β dysbiosis increases abundance of Gram-negative Proteobacteria producing LPS, driving systemic Endotoxaemia (>50 pg/mL) and chronic TLR4 activation
- chronic low-grade inflammation β dysbiosis is a major upstream cause via LPS translocation, reduced Treg induction, and loss of anti-inflammatory SCFA signaling
- antibiotics β primary iatrogenic cause of dysbiosis in developed nations; effects persist 6-12 months minimum; repeated courses cause irreversible diversity loss
- Western diet β low fiber (<15g/day) combined with high fat/sugar drives dysbiosis within 24-72 hours by starving SCFA-producers and promoting pathobiont bloom
- chronic stress β alters gut microbiome through sympathetic nervous system activation and Cortisol β reduced splanchnic perfusion, Noradrenaline secretion stimulating pathobiont virulence
- SCFA β dysbiosis reduces total Short-chain fatty acids by 50-70%, eliminating key metabolic signals for colonocyte health, GLP-1 secretion, Treg expansion, and GPR41/GPR43 activation
- secretory IgA β dysbiosis impairs salivary IgA production via reduced B-cell stimulation from commensals, compromising immune exclusion of pathogens at mucosal surfaces
- Depression β dysbiosis contributes through multiple mechanisms: reduced Tryptophan metabolism β decreased serotonin; increased Kynurenic acid via IDO activation; LPS-driven IL-6 β hippocampal inflammation
- obesity β dysbiosis characterized by reduced diversity, altered Firmicutes/Bacteroidetes ratio (though controversial), increased energy harvest from diet, and impaired satiety signaling via reduced GLP-1
- Type 2 Diabetes β dysbiosis impairs glucose metabolism through Endotoxaemia β hepatic Insulin resistance, reduced GLP-1 secretion, and impaired SCFA β GPR43 β adiponectin pathway
- autoimmune disease β dysbiosis promotes autoimmunity via Molecular Mimicry (bacterial antigens cross-react with self-antigens), barrier compromise allowing antigen presentation, and reduced Treg suppression
- probiotics β therapeutic intervention providing Lactobacillus, Bifidobacterium, or Saccharomyces strains; effects are strain-specific and temporary without concurrent dietary fiber increase
- prebiotics β non-digestible fibers (inulin, FOS, resistant starch, beta-glucans) that selectively stimulate beneficial bacteria growth; most effective dysbiosis intervention when combined with probiotics
- fecal microbiota transplantation β most effective intervention for severe dysbiosis; 90% cure rate for C. difficile; emerging evidence for Ulcerative Colitis, metabolic syndrome, and neuropsychiatric disorders
- NSAIDs β cause dysbiosis through direct antimicrobial effects (selective killing of Bifidobacterium) and gut barrier damage via COX-1 inhibition reducing protective prostaglandins
- Akkermansia-muciniphila β mucin-degrading bacteria maintaining mucus layer integrity; depletion in dysbiosis correlates with barrier dysfunction and metabolic disease
- Bifidobacterium β early colonizer in infancy; produces acetate and lactate feeding Butyrate-producers; depletion in dysbiosis associates with immune dysregulation and allergy
- bile acids β dysbiosis impairs bacterial bile acid dehydroxylation, reducing secondary bile acids that activate TGR5 and FXR for metabolic regulation
- Tryptophan β dysbiosis reduces bacterial Tryptophan metabolism to beneficial indole derivatives, shifting hepatic metabolism toward inflammatory kynurenine pathway
- inflammatory bowel disease β Faecalibacterium depletion correlates with disease activity in both Crohn's disease and Ulcerative Colitis; dysbiosis precedes clinical relapse by weeks
- Insulin resistance β dysbiosis-driven Endotoxaemia activates hepatic TLR4 β JNK β serine phosphorylation of IRS-1, blocking insulin signaling
- Treg cells β dysbiosis impairs Treg induction via reduced Butyrate (histone deacetylase inhibitor promoting Foxp3 expression) and reduced TGF-beta from tolerogenic dendritic cells
- vagus nerve β dysbiosis signals to brain via vagal IL-1Ξ² receptors on paraganglia cells, contributing to sickness behavior and depressive symptoms
- Endotoxaemia β dysbiosis is primary cause of metabolic endotoxemia (plasma LPS 10-50 pg/mL), driving chronic inflammatory disease via TLR4 activation
ΒΆ Module References
- Module 1: Introduction to cPNI β dysbiosis as upstream driver of chronic low-grade inflammation and immune dysregulation affecting brain function
- Module 6: Gut and microbiome β primary module covering dysbiosis mechanisms, assessment, and intervention strategies
- Module 7: Immune system β dysbiosis effects on immune tolerance, Treg function, and autoimmune disease pathogenesis